Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.37 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL580023 | 0.86 | POLB (0.52) | LMNAMAPTKDM4EALDH1A1GAA | |
| SCHEMBL378051 | 0.83 | KDM4E (0.53) | LMNAMAPTKDM4EALDH1A1GAA | |
| SCHEMBL8571227 | 0.78 | CYP3A4 (0.50) | LMNAMAPTKDM4EALDH1A1GAA | |
| SCHEMBL4639714 | 0.77 | POLB (0.53) | LMNAMAPTKDM4EALDH1A1POLB | |
| SCHEMBL17831137 | 0.77 | POLB (0.44) | LMNAMAPTKDM4EPOLBMEN1 | |
| SCHEMBL3631470 | 0.75 | KDM4E (0.46) | LMNAMAPTKDM4EPOLBMEN1 | |
| SCHEMBL28401117 | 0.75 | KDM4E (0.60) | LMNAKDM4EALDH1A1GAAPOLB | |
| SCHEMBL988444 | 0.75 | KDM4E (0.48) | LMNAMAPTKDM4EALDH1A1GAA | |
| SCHEMBL28269321 | 0.74 | POLB (0.46) | LMNAMAPTKDM4EALDH1A1POLB | |
| SCHEMBL1875080 | 0.74 | ALDH1A1 (0.53) | LMNAALDH1A1GAAPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408454-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2024-07-24 | — | — | EP | disclosed |
| US-11407719-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2022-08-09 | — | — | US | disclosed |
| US-20210361656-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2021-11-25 | — | — | US | disclosed |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2021-03-11 | — | — | US | disclosed |
| US-10882828-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2021-01-05 | — | — | US | disclosed |
| US-20200352946-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2020-11-12 | — | — | US | disclosed |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2019-04-25 | — | — | US | disclosed |
| US-10131640-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2018-11-20 | — | — | US | disclosed |
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2018-04-19 | — | — | US | disclosed |
| CN-105859639-A | NOVEL ANTI-INFLAMMATORY AGENTS | 雷斯韦洛吉克斯公司 | 2016-08-17 | — | — | CN | disclosed |
| WO-2013175281-A1 | USE OF SUBSTITUTED 2-PHENYL-3H-QUINAZOLIN-4-ONES AND ANALOGS FOR INHIBITING BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) PROTEINS | RVX THERAPEUTICS INC. (CA) | 2013-11-28 | — | — | WO | disclosed |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| WO-2013156869-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | WO | disclosed |
| US-20130281397-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-02-16 | — | — | US | disclosed |
| EP-2408454-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-01-25 | — | — | EP | disclosed |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2012-01-19 | — | — | US | disclosed |
| US-8053440-B2 | Compounds for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2011-11-08 | — | — | US | disclosed |
| WO-2010106436-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-09-23 | — | — | WO | disclosed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | LMNA 489/4885MAPT 3436/4885KDM4E 4404/4885 |
| US-11407719-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | LMNA 3612/4885MAPT 2112/4885KDM4E 3982/4885 |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | PHKB, BAZ2A, EP300 | LMNA 1601/4885MAPT 1238/4885KDM4E 342/4885 |
| US-10882828-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | LMNA 3612/4885MAPT 2112/4885KDM4E 3982/4885 |
| US-20130281397-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | BRD4, BMI1, BRPF3 | LMNA 1294/4885MAPT 2454/4885KDM4E 202/4885 |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | LMNA 3612/4885MAPT 2112/4885KDM4E 3982/4885 |
| US-20210361656-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | LMNA 489/4885MAPT 3436/4885KDM4E 4404/4885 |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | LMNA 489/4885MAPT 3436/4885KDM4E 4404/4885 |
| US-10131640-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | LMNA 3612/4885MAPT 2112/4885KDM4E 3982/4885 |
| US-20200352946-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | LMNA 489/4885MAPT 3436/4885KDM4E 4404/4885 |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | APOB, LDLR, APOL1 | LMNA 993/4885MAPT 3320/4885KDM4E 2993/4885 |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | LMNA 3769/4885MAPT 2027/4885KDM4E 3726/4885 |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | LMNA 3769/4885MAPT 2027/4885KDM4E 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.